MarketPulse

BPL-003

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's BPL-003 Shows Durable Antidepressant Benefits in Treatment-Resistant Depression

AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.
ATAIPhase 3 clinical trialtreatment-resistant depression
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval